...
首页> 外文期刊>International immunopharmacology >Immunological and protective effects of Bordetella bronchiseptica subunit vaccines based on the recombinant N-terminal domain of dermonecrotic toxin
【24h】

Immunological and protective effects of Bordetella bronchiseptica subunit vaccines based on the recombinant N-terminal domain of dermonecrotic toxin

机译:基于皮肤坏死毒素重组N末端结构域的支气管败血波氏杆菌亚单位疫苗的免疫和保护作用

获取原文
获取原文并翻译 | 示例
           

摘要

Dermonecrotic toxin (DNT) produced by Bordetella bronchiseptica (B. bronchiseptica) can cause clinical turbinate atrophy in swine and induce dermonecrotic lesions in model mice. We know that the N-terminal of DNT molecule contains the receptor-binding domain, which facilitates binding to the target cells. However, we do not know whether this domain has sufficient immunogenicity to resist B. bronchiseptica damage and thereby to develop a subunit vaccine for the swine industry. In this study, we prokaryotically expressed the recombinant N-terminal of DNT from B. bronchiseptica (named DNT-N) and prepared it for the subunit vaccine to evaluate its immunogenicity. Taishan Pinus massoniana pollen polysaccharide (TPPPS), a known immunomodulator, was used as the adjuvant to examine its immune-conditioning effects. At 49 d after inoculation, 10 mice from each group were challenged with B. bronchiseptica, and another 10 mice were intradermally challenged with native DNT, to examine the protection imparted by the vaccines. The immune parameters (T-lymphocyte counts, cytokine secretions, serum antibody titers, and survival rates) and skin lesions were determined. The results showed that pure DNT-N vaccine significantly induced immune responses and had limited ability to resist the B. bronchiseptica and DNT challenge, whereas the mice administered with TPPPS or Freund's incomplete adjuvant vaccine could induce higher levels of the above immune parameters. Remarkably, the DNT-N vaccine combined with TPPPS adjuvant protected the mice effectively to prevent B. bronchiseptica infection. Our findings indicated that DNT-N has potential for development as an effective subunit vaccine to counteract the damage of B. bronchiseptica infection, especially when used conjointly with TPPPS. (C) 2015 Elsevier B.V. All rights reserved.
机译:支气管败血博德特氏菌(B. bronchiseptica)产生的皮肤坏死毒素(DNT)可以引起猪临床鼻甲萎缩并在模型小鼠中诱发皮肤坏死性病变。我们知道,DNT分子的N端含有受体结合域,这有助于与靶细胞结合。但是,我们不知道该结构域是否具有足够的免疫原性来抵抗支气管败血性芽孢杆菌的损害,从而开发出用于养猪业的亚单位疫苗。在这项研究中,我们原核表达了支气管败血性博德特氏菌DNT的重组N端(命名为DNT-N),并将其准备用于亚单位疫苗以评估其免疫原性。泰山马尾松花粉多糖(TPPPS),一种已知的免疫调节剂,被用作佐剂来检查其免疫调节作用。接种后49天,用支气管败血性博德氏杆菌攻击每组的10只小鼠,用天然DNT皮内攻击另外10只小鼠,以检查疫苗赋予的保护作用。确定了免疫参数(T淋巴细胞计数,细胞因子分泌,血清抗体滴度和存活率)和皮肤损伤。结果表明,纯DNT-N疫苗可显着诱导免疫反应,抵抗支气管败血性芽孢杆菌和DNT攻击的能力有限,而施用TPPPS或弗氏不完全佐剂疫苗的小鼠可诱导更高水平的上述免疫参数。值得注意的是,DNT-N疫苗与TPPPS佐剂结合可有效保护小鼠,从而预防支气管败血性博德特氏菌感染。我们的发现表明,DNT-N有潜力作为一种有效的亚单位疫苗来对抗支气管败血性芽孢杆菌感染的损害,特别是与TPPPS联合使用时。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号